Drug intelligence / Profile preview

NRCT-202SR

Development stage: Unknown
Lead developer: Neurocentria
Modality: Small Molecules
Administration: Oral

Overview

NRCT-202SR is a sustained-release small molecule drug candidate developed by Neurocentria for the treatment of Alzheimer's disease. The drug's mechanism of action involves elevating intracellular magnesium (Mg2+) levels in the brain, which serves to modulate N-methyl-D-aspartate (NMDA) receptor activity and improve the function of glutamatergic synapses. By increasing synaptic density and enhancing synaptic plasticity, NRCT-202SR aims to address the cognitive decline and neurodegeneration associated with Alzheimer's. It is currently in Phase 2 clinical development and represents a pharmaceutical-grade formulation distinct from over-the-counter magnesium supplements.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on NRCT-202SR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRCT-202SR.

Explore the full profile